VALBIOTIS aims to revolutionize healthcare by developing a new class of products designed to reduce the risk of major metabolic diseases, for which there is currently no satisfactory medical solution.
These innovative products are intended for people at risk of developing type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and/or cardiovascular diseases.
From a medical point of view, the products developed by VALBIOTIS form part of a global preventive approach to treatment and are designed to complement existing recommendations for a healthy lifestyle and diet.
As with type 2 diabetes, metabolic diseases are chronic and complex: their physiopathology cannot be attributed to the dysfunction of a single tissue or a specific receptor.
The onset of type 2 diabetes, for example, notably involves impaired function of the liver, pancreas, adipose tissue or skeletal muscle. Recent research has also confirmed a link between diabetes and a change in the composition of the intestinal microbiota.
Sources: Everard A., Cani P., Diabetes, obesity and gut microbiota, Best Practice & Clinical Research in Gastro-enterology, 2013;
De Fronzo et al.,Type 2 Diabetes Mellitus, Nature Reviews, 2015
VALBIOTIS has adopted an innovative strategy in order to prevent these diseases: to develop products that can simultaneously act on different physiological targets of interest. This multi-targeted or pleiotropic mode of action optimizes the clinical effects of our products on the metabolism.
Thanks to their pharmacological wealth, plants represent a very useful resource for this strategy: each plant from a given species is composed of a set of distinct active molecules known as the “Totum”, obtained via a suitable extraction method.
To harness the potential of plants, VALBIOTIS has developed specific, high-level expertise in a range of fields such as biochemistry, bioengineering and the physiopathology of metabolic disorders.
The biomolecule complexes of plant origin developed by VALBIOTIS are the result of advanced work in analytical chemistry and systematic in vivo screening. This approach makes it possible to select plant extracts according to their benefits, and to identify complementary combinations of active biomolecules on the physiopathology of metabolic diseases, thus optimizing their efficacy.
This innovative work by Research and Development adds value in terms of intellectual property: VALBIOTIS products are subject to a protection strategy for their composition and clinical use, on a global scale.
In the world of healthcare products, VALBIOTIS has chosen to adopt an innovative position: to develop new products from natural plant origin according to the clinical standards of evidence-based medicine.
All of our preclinical studies are conducted using metabolic disease models and specific cellular cultures, to obtain proof of concept and characterize the mechanisms of action of the active ingredients.
The clinical plans then aim to guarantee the safety of products and unequivocally demonstrate their efficacy in reducing the risk factors of major metabolic diseases such as type 2 diabetes, NASH, obesity and cardiovascular diseases.
The aim of clinical development: to obtain specific health claims for each product recognized by regulatory authorities such as the FDA (Food and Drug Administration, United States) and the EFSA (European Food Safety Authority, Europe), which constitute a guarantee of clinical efficacy. Therefore transparency is an important requirement.
400 people in total will be included in the clinical development plan for VALEDIA®.
clinical studies on 4 products of the pipeline, including 3 already completed, 1 currently underway and 5 which should be launched in 2019.
areas will be targeted as a priority: the United States (FDA), Canada (Santé Canada) and Europe (EFSA).
patent families filed by VALBIOTIS since 2014.